For example, adalimumab, etanercept, and infliximab are agents that inhibit tumor necrosis factor-alpha (TNF-α), that is overexpressed in several autoimmune diseases, such as ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, Crohn's disease, and rheumatoid arthritis [8–12]. Here, TNF is linked to ankylosing spondylitis.